# Low Life Expectancy in the United States: Is the Health Care System at Fault? 

Samuel H. Preston<br>University of Pennsylvania, spreston@sas.upenn.edu<br>Jessica Y. Ho<br>University of Pennsylvania, yjho@sas.upenn.edu PSC 09-03.

Low Life Expectancy in the United States: Is the Health Care System at Fault?*

Samuel H. Preston<br>Jessica Ho

Population Studies Center<br>University of Pennsylvania


#### Abstract

Life expectancy in the United States fares poorly in international comparisons, primarily because of high mortality rates above age 50. Its low ranking is often blamed on a poor performance by the health care system rather than on behavioral or social factors. This paper presents evidence on the relative performance of the US health care system using death avoidance as the sole criterion. We find that, by standards of OECD countries, the US does well in terms of screening for cancer, survival rates from cancer, survival rates after heart attacks and strokes, and medication of individuals with high levels of blood pressure or cholesterol. We consider in greater depth mortality from prostate cancer and breast cancer, diseases for which effective methods of identification and treatment have been developed and where behavioral factors do not play a dominant role. We show that the US has had significantly faster declines in mortality from these two diseases than comparison countries. We conclude that the low longevity ranking of the United States is not likely to be a result of a poorly functioning health care system.


[^0]The United States falls well behind the world's leaders in life expectancy at birth. Some of the discrepancy is attributable to relatively high infant mortality and some to high mortality from violence among young adults. But the bulk of the discrepancy is attributable to mortality above age 50, an age to which $94 \%$ of newborns in the United States will survive according to the 2006 US life table. Life expectancy at age 50 in the United States ranks $29^{\text {th }}$ highest in the world in 2006 according to the World Health Organization (WHO 2009). It falls 3.3 years behind the leader, Japan, and more than 1.5 years behind Australia, Canada, France, Italy, Iceland, Spain, and Switzerland. About 4 million Americans reach age 50 each year, so that an average loss of 1.5 years of life years per person means that some 6 million years of potential life are being lost annually. At the conventional value of $\$ 100,000$ per additional year of life (Cutler 2004), the relative loss of life in the US above age 50 is valued at roughly $\$ 600$ billion annually. Using Japan as a standard, the loss is $\$ 1.3$ trillion.

Analysts often juxtapose the poor ranking of the United States in life expectancy and the very high percentage of its gross national product that is spent on health care. In 2007, the United States spent $16 \%$ of its GDP on health care, by far the highest fraction of any country (Congressional Budget Office 2007). The conclusion that is often drawn from this combination is that the United States' health care system is extremely inefficient (e.g., Anderson and Frogner 2008).

But measures of population health such as life expectancy do not depend only on what transpires within the health care system - the array of hospitals, doctors and other health care professionals, the techniques they employ, and the institutions that govern access to and utilization of them. Such measures also depend upon a variety of personal behaviors that affect an individual's health such as diet, exercise, smoking, and compliance with medical protocols. The health care system could be performing exceptionally well in identifying and administering treatment for various diseases, but a country could still have poor measured health if personal health care practices were unusually deleterious. This is not a remote possibility in the United States, which had the highest level of cigarette consumption per capita in the developed world over a 50 -year period ending in the mid-80's (Forey et al. 2002). Smoking in early life has left an imprint on mortality patterns that remains visible as cohorts age (Preston and Wang 2006; Haldorsen and Grimsrud 1999). One recent study estimated that, if deaths attributable to smoking were eliminated, the ranking of US men in life expectancy at age 50 among 20 OECD
countries would improve from $14^{\text {th }}$ to $9^{\text {th }}$, while US women would move from $18^{\text {th }}$ to $7^{\text {th }}$ (Preston, Glei, and Wilmoth 2009). Recent trends in obesity are also more adverse in the United States than in other developed countries (OECD 2008; Cutler, Glaeser, and Shapiro 2003).

This paper begins with a review of previous international studies of the comparative performance of health care systems. The review is focused on the major diseases of adulthood, cancer and cardiovascular disease, in the belief that disease-level analyses are more likely to reveal the forces at work than more highly aggregated studies (Garber 2003). In 2005, cancer and major cardiovascular diseases were responsible for $61.0 \%$ of deaths in the US at ages 45+ (US National Center for Health Statistics 2008). Because our concern is with mortality per se, the criterion we employ is effectiveness at preventing death, rather than cost-effectiveness or efficiency of resource deployment. These latter criteria have been used in several other recent comparative studies with a financial focus (Garber and Skinner 2008; McKinsey Global Institute 2008).

Health systems can prevent death from a particular disease either by preventing a disease from developing or by effectively treating it once it has developed. A key element in effective treatment is accurate diagnosis. Unfortunately, almost no internationally comparable data exist on the actual incidence of various diseases, which is the appropriate measure of the success of prevention. While cancer appears to be an exception because "incidence" data are published for various cancer registry sites (e.g., at the website of the International Agency for Research on Cancer), the data refer not to the origin of a disease but to its detection, a process that combines actual patterns of incidence with the mechanics of identification. And even if pure measures of it were available, actual disease incidence reflects not only features of a health system but also many other factors of behavioral, social, and genetic origin.

Disease prevalence - the proportion of the population that has been diagnosed with a disease - is even more difficult to interpret. The United States has a higher prevalence than Europe of the major adult diseases, including cancer, heart disease, and diabetes (Thorpe et al. 2007a; Avendano et al. 2009). But higher prevalence could reflect higher incidence, better detection, or longer survival resulting from more successful treatment. Because of these limitations of data and interpretation, our review will focus primarily on disease identification and treatment, elements that are customarily considered to be the provenance of health care systems.

A valuable but not unimpeachable indicator of the effectiveness of treatment is the comparative survival rate of individuals once a disease has been detected. Relatively high survival rates imply either that the disease has been detected unusually early or that treatment is unusually successful. Early detection is valuable to the extent that it permits better therapy. However, if early detection did not alter the clinical course of a disease but only increased the expected length of time from detection to death (so-called "lead time bias"), then it would not be associated with reductions in mortality at the population level despite raising 5-year survival rates (e.g., Gatta et al. 2000).

Because they are not subject to this potential bias, we pay special attention to mortality rates. In particular, in the second half of the paper we investigate comparative mortality trends for prostate cancer and breast cancer. We document that

- effective methods of screening for these diseases have been developed relatively recently;
- these diagnostic methods have been deployed earlier and more widely in the US than in most comparison countries;
- effective methods are being used to treat these diseases; and
- the US has had a significantly faster decline in mortality from these diseases than comparison countries.


## International Studies of Cancer

The United States does well in international comparisons of the frequency of cancer screening. The OECD $(2006,2007)$ provides $2000-05$ data on the percentage of women aged 20 69 in 15 countries who had been screened for cervical cancer during the preceding three years. The US has the highest percentage of women who have been screened in both tabulations. ${ }^{1}$ We present evidence below that the US also has exceptionally high screening rates for prostate cancer and breast cancer. Quinn (2003) reports colorectal screening rates in the US that are "quite high" in comparison to Europe but does not provide comparative data. Gatta et al. (2000: 899) also suggest that access to and use of sigmoidoscopy, colonoscopy, and fecal occult blood tests are more common in the US than in Europe. This difference is supported by the finding that

[^1]colorectal cancer patients in the US have less advanced disease at diagnosis than patients in Europe (Ciccolallo et al. 2005).

A higher rate of screening for cancer would produce a higher prevalence of everdiagnosed cancer in the population, ceteris paribus. The elevated prevalence would occur simply because a higher fraction of the population would know about their disease. An additional boost to prevalence would be provided if early detection resulted in reduced mortality. Thus, in view of the higher frequency of screening in the US, we would expect its reported prevalence of diagnosed cancer to be higher than in Europe.

That expectation is confirmed by data from the Health and Retirement Survey and its English and European counterparts. Thorpe et al. (2007a) find that $12.2 \%$ of Americans over age 50 report having been diagnosed by physicians with cancer, compared to only $5.4 \%$ in a composite of 10 European countries. Avendano et al. (2009) report similar figures for the age range 50-74, with England intermediate between the US and Europe but closer to Europe. Some fraction of these very large differences in prevalence could, of course, be attributable to real differences in disease incidence or to reporting differences, which are discussed briefly below.

Thanks to a large number of cancer registries that record new cancer diagnoses and follow individuals forward from the point of diagnosis, 5 -year survival rates for people initially diagnosed with cancer are widely available to provide evidence about the success of detection and treatment. Because of their relative comparability and pertinence to a major disease process, these data are among the best indicators of comparative health system performance. In this summary, we use 5-year relative survival rates, which compare the survival of those diagnosed with cancer to that of an average person of the same age and sex as the person diagnosed.

International comparisons of cancer survival rates show a distinct advantage for the US. Using cancer registry data, researchers from the Eurocare Working Group compare 5-year survival rates for cancers of 12 sites that were diagnosed between 1985 and 1989 (Gatta et al. 2000). The aggregate of 41 European registries, which were drawn from 17 countries, had lower survival rates than the US from all cancer sites except the stomach, where differences were small and attributed to differences between the distributions of sites within the stomach. The US data were drawn from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database, a population-based cancer registry covering approximately $14 \%$ of the US population. For the major sites of lung, breast, prostate, colon, and rectum cancers, US survival
rates were the highest of any of the 18 countries investigated. Cancers first diagnosed on the death certificate ( $5 \%$ in Europe and $1 \%$ in the US) were excluded from analysis; if they had been included, the US survival advantage would have increased. The authors discount the possibility that the US advantage was attributable to statistical or registration artifacts.

An updated analysis reached similar conclusions. Based upon period survival data for 2000-02 from 47 European cancer registries, 5-year survival rates were found to be higher in the US than in a European composite for cancer at all major sites (Verdecchia et al. 2007). Table 1 presents the comparative data for all sites for which the US $95 \%$ confidence interval was $<0.025$. For men (all sites combined), $47.3 \%$ of Europeans survived 5 years, compared to $66.3 \%$ of Americans. For women, the contrast was $55.8 \%$ vs. $62.9 \%$. The male survival difference was much greater than the female primarily because of the very large difference in survival rates from prostate cancer.

Thus, the US appears to screen more vigorously for cancer than Europe and people in the US who are diagnosed with cancer have higher 5-year survival probabilities. Scattered data for cancer of various sites indicate that tumors are typically detected at an earlier stage in the US (Gatta et al. 2000; Sant et al. 2004; Ciccolallo et al. 2005). Of course, all of these phenomena could be the exclusive product of lead-time bias if early detection afforded no benefit for the clinical course of the disease. Below, we present evidence that innovations in diagnosis and treatment of prostate and breast cancer were associated with faster declines in mortality in the US than in OECD countries. Such a pattern would not be observed if lead time bias were the only factor at work, i.e., if early detection conferred no advantage.

## International Studies of Cardiovascular Disease

In contrast to cancer, nations do not have registries for heart disease and stroke. So information about the comparative performance of medical systems in respect to cardiovascular disease is not as systematic and orderly as it is for cancer. One useful source of comparative data is the Health and Retirement Survey (HRS) and its European counterparts, the Survey of Health, Aging, and Retirement in Europe (SHARE). Thorpe et al. (2007a) compare the US to a composite of 10 European countries on the frequency with which people with a particular diagnosis report using medication. Of people aged 50+ diagnosed with heart disease, $60.7 \%$ of Americans and $54.5 \%$ of Europeans report being on medication. The proportions using
medication after a stroke are comparable at $45.1 \%$ and $44.6 \%$. Of those reporting high cholesterol levels, $88.1 \%$ of Americans report being medicated vs. $62.4 \%$ of Europeans. ${ }^{2}$ Crimmins, Garcia, and Kim (2009) show that a much higher fraction of Americans are using lipid-lowering drugs at a particular age than in Japan, the Netherlands, or Italy, even though proportions with elevated cholesterol in these countries are similar to or higher than that in the US.

Among those reporting high blood pressure in HRS and SHARE, the proportions reporting taking medication for the condition are similar in the US (88.0\%) and Europe (88.9\%) (Thorpe et al. 2007a). However, when actual measures of blood pressure are used rather than self reports, the position of the US improves. Wolf-Maier et al. (2004) employ regional or national samples in the US, Canada, and five European countries. Hypertension is defined as the population of persons who have systolic blood pressure of 160+ or diastolic blood pressure of $95+$ or who are using antihypertensive medication. Of persons aged 35-64 with hypertension, $77.9 \%$ were being treated in the US, compared to a range of $41.0 \%-62.4 \%$ in the other six countries. Among those with hypertension, $65.5 \%$ were being successfully treated in the US (i.e., their levels were reduced below the hypertension-defining threshold), compared to $24.8 \%$ to $49.1 \%$ in the other countries.

Survival data for cardiovascular disease start not from the point of diagnosis but from an acute event of heart attack or stroke. An OECD study, following up on a study by the TECH network, computed one-year case fatality rates for people hospitalized for acute myocardial infarction (AMI) in Australia, Canada, Denmark, Finland, Sweden, Great Britain, and the US. The samples were sometimes regionally rather than nationally representative. Among the seven countries in 1996, the US had the third lowest case-fatality rate for males aged 40-64 and the second-lowest rate for men aged 85-89. For women at these ages, the US ranked fourth and first (Moise 2003). Part of the explanation of the better performance of the US may be related to its unusually aggressive treatment regime. Of the seven countries, the US had the highest proportion of male and female patients in both age intervals undergoing revascularization operations (percutaneous transluminal coronary angioplasty or coronary artery bypass graft) (Ibid.; see also

[^2]Technological Change in Health Care (TECH) Research Network 2001). ${ }^{3}$
One study has explicitly linked more aggressive surgical treatment in the US to better outcomes. It compared Canadians and Americans who had just experienced an AMI and who enrolled in a drug trial (Kaul et al. 2004). Data are not nationally representative but rather reflect the patient-base of hospitals participating in the trial. Americans had a small but statistically significant advantage in 5-year survival. Controlling many baseline characteristics, the hazard rate was $17 \%$ higher in Canada. When revascularization was added to the model, it was associated with a $28 \%$ reduction in the hazard rate and its addition reduced the international difference to an insignificant 7\%. The authors conclude that "...our findings are strongly suggestive of a survival advantage for the US cohort based on more aggressive revascularization" (Ibid., p. 1758).

OECD (2003) has conducted a large international study of ischaemic stroke, which accounts for roughly $88 \%$ of stroke cases except in Japan, where it represents about $70 \%$. They calculate in-hospital 7-day and 30-day survival rates for patients newly admitted with ischaemic stroke. For both men and women aged 65-74, the US ranking on 7-day survival rates was $3^{\text {rd }}$ out of 9 ; at ages $75+$, it was $2^{\text {nd }}$ out of 9 for both sexes. For 30 -day hospital survival rates at ages 65 74 , the US was $2^{\text {nd }}$ for women and tied for $2^{\text {nd }}$ with two others among men. At ages $75+$, the US 30 -day survival rate was $1^{\text {st }}$ for men and $2^{\text {nd }}$ for women. Counting all deaths and not simply deaths in the hospital, and limiting comparison to six regions including two in Canada, the US survival rate ranked $1^{\text {st }}$ for men aged 65-74 and 75+ and second for women in these ages. However, the US one-year survival rate among this set of populations was considerably poorer, ranking $5^{\text {th }}$ of 6 for men aged 65-74 and $4^{\text {th }}$ of 6 for men aged $75+$. For women at these two ages, the rankings were $4^{\text {th }}$ and $3^{\text {rd }}$. Consistently in these rankings, the US position was better at $75+$ than at 65-74.

Carotid endarterectomy (surgical removal of plaque from inside the carotid artery) is used to prevent stroke or the recurrence of stroke. Such surgery is much more common in the US than in any of 11 comparison OECD countries (OECD 2003). We are unaware of any studies linking this surgery to international patterns of stroke mortality, but a randomized clinical trial reports a large survival advantage for persons undergoing the procedure (Halliday et al. 2004).

[^3]
## Contrary Evidence? "Mortality Amenable to Medical Care"

The Commonwealth Fund (2008) has recently issued a "scorecard" on US health system performance that consists of 37 indicators. The highly publicized report concludes that the United States lags far behind its peers in measures of health system performance. Most of the indicators use benchmarks that are established by consultation with experts or by values in bestperforming states. But several are based on international comparisons. The international index that receives the most attention is "Mortality amenable to medical care", on which the US currently ranks last among 19 countries. This index is developed and applied in Nolte and McKee (2008), where amenable deaths are described as "deaths from certain causes that should not occur in the presence of timely and effective health care" (p. 59). Only deaths below age 75 are included, which constitute $43.2 \%$ of deaths in the US in 2005 (US National Center for Health Statistics 2008). For some causes of death, an earlier age cutoff is used.

The distribution of major causes of death included among the "amenable causes" is provided for the US, the United Kingdom, and France (Nolte and McKee 2008). A majority of amenable deaths in all three countries is attributed to ischemic heart disease and other circulatory diseases, even though only half of ischemic heart disease deaths are included because some are believed not to be amenable to health care. That rule of thumb is clearly a poor substitute for an effort to attribute international variation in mortality from ischemic heart disease to its various components, including health care systems and behavioral and social factors. ${ }^{4}$ The authors note that a similar rule of thumb could have been introduced for cerebrovascular diseases, which constitute at least a quarter of the "amenable" deaths in the US and UK. But it would have been no more satisfactory for that cause of death.

In view of the studies that show that the US does relatively well in treating cardiovascular disease, it seems inaccurate to attribute its high death rates from these causes to a poorly performing medical system. And these diseases contribute a majority of their set of amenable deaths, rendering the totality of amenable causes problematic. A related objection could be raised to the inclusion of diabetes deaths in the set. On the other hand, prostate cancer is excluded from the list of amenable causes despite the fact that the 5-year survival rate from prostate cancer in the US is above $99 \%$ and the disease can be readily identified (see below).

[^4]According to Nolte and McKee (2008), males in the United States had a faster fall in mortality from non-amenable causes of death (an $8 \%$ decline) than from amenable ones (4\%) between the latest two readings, 1997/8 and 2002/3. This anomaly suggests either flaws in the index or the unimportance of medical care relative to other factors that are operating.

Causes of death whose inclusion in Nolte and McKee's list of amenable causes at older ages is more defensible are influenza and pneumonia. Mortality from both causes is heavily influenced by smoking (Centers for Disease Control and Prevention 2002), so the international distribution of mortality is a product of factors beyond the health care system. On the other hand, influenza is partially immunizable and death from pneumonia can often be avoided through administration of vaccines or antibiotics or improvements in hospital sanitation.

The US ranks $9^{\text {th }}$ of 23 OECD countries in the proportion of the population above age 65 offered an annual influenza vaccination (OECD 2007). Figure 1 demonstrates that the 2000-04 age-standardized death rate from influenza at ages 50+ in the United States is among the lowest of the 16 countries investigated. The US fares less well in mortality from pneumonia, ranking $6^{\text {th }}$ worst among the 16 countries investigated (Figure 2). However, the ranking is somewhat deceiving because its death rate is closer to all but one of the better-ranked countries than to the five countries with higher rates. The US death rate from pneumonia at ages 50+ is actually below the weighted or unweighted mean for the other 15 countries.

## Disease Prevention

Medical procedures and survival rates are indicators of what happens to individuals whose health problems come to the attention of the health care system. But a health care system can also help prevent serious health problems from occurring in the first place. Of course, early identification of a disease is also preventative medicine in the sense that it may prevent death. But access to preventive medicine would appear to be an especially problematic area in the United States because 47 million people lack any form of health insurance (DeNavas-Walt, Proctor, and Smith 2007). ${ }^{5}$ Such people are less likely to see a doctor and thus to receive routine testing that might detect the early stages of a disease and prevent its clinical manifestations (Institute of Medicine 2001). They are also less likely to receive advice about health maintenance

[^5]and disease prevention (Ibid.).
An additional factor that may inhibit disease prevention in the US is the shortage of primary care physicians. The US scores in the bottom group of 6 out of 18 OECD countries on a scale of the adequacy of primary care (Macinko, Starfield, and Shi 2003). The scale is built from items relating to policy, finances, and personnel. In turn, the adequacy of primary care may be related to disease prevention (Ibid.)

The best indication of the success of prevention is disease incidence. But international data on disease incidence are nil. As noted earlier, disease prevalence is higher in the US than in a European composite for cancer, heart disease, stroke, chronic lung disease, and diabetes (Thorpe et al. 2007a). However, such a difference could result from higher incidence in the US, better detection, or longer survival after detection. It could also result from reporting differences, e.g., a greater inclination to report disease in the US. But a careful study by Banks et al. (2006) using biomarkers suggests that morbidity differences between England and the US at ages 55 to 64 are real and not a result of differences in reportage. One related study found that, faced with the same set of health-related vignettes, Americans were less likely to report themselves as disabled than the Dutch (Kapteyn, Smith, and van Soest 2007).

Even if incidence data were available, analysts would have to disentangle the role of personal behavioral and social histories from that of health system performance. And these are not always readily distinguishable. Are the historically high rates of smoking in the US attributable to the failure of the US public health system to stem the smoking tide? The fact that Canada had for many years the second highest consumption of cigarettes per adult (Forey et al. 2002) makes it appear that geographic factors, perhaps related to conditions for growing or importing tobacco, had more to do with consumption patterns than did health systems. And public health authorities were not passive in the US. The US Surgeon General's (1964) report on the health hazards of cigarette smoking was the first major indictment of the habit by a government authority and it was quickly followed up with a massive anti-smoking media campaign (Cutler and Glaeser 2006). The US had the largest reduction in manufactured cigarettes consumed per adult of any country between 1970 and 2000 (Forey et al. 2002). Some of that decline was likely attributable to public health efforts (Cutler and Glaeser 2006).

However it is achieved, the high prevalence of disease in the US adds considerably to health expenditure. Thorpe et al. (2007b) combine comparative prevalence data on 10 conditions
in HRS (in the US) and SHARE (in Europe) with Agency for Healthcare Research and Quality data on expenditure per medical condition for the population aged 50+. Their $95 \%$ confidence intervals on the per capita cost of higher disease prevalence in the US are $\$ 1,195$ to $\$ 1,750$ per year, or 12.7 to $18.7 \%$ of total personal health care spending among those aged 50+.

Inefficiencies in the health care system are not solely responsible for high per capita health expenditures in the US; the high prevalence of major diseases is also substantially implicated (see also Michaud et al. 2009).

## Case Study I. Prostate Cancer

Accounting for 31,000 deaths in 2000, prostate cancer was, after lung cancer, the second leading cause of cancer deaths among US men that year (US National Center for Health Statistics 2002). Unlike most chronic diseases, it is not associated with cigarette smoking (Lumey et al. 1997). A link with exercise has been suggested in several studies but a review article found that "conclusions were quite variable... odds ratios [of developing prostate cancer] for men engaged in high levels of activity ranged from 0.2 to over 2.0" (Torti and Matheson 2004). Dietary risk factors are suspected but not well established. The risk of prostate cancer is somewhat higher for men with a high body mass index, but the risk is less than for other cancers (Crawford 2003). Genetic factors, some of them associated with race, appear to be important in the risk of developing prostate cancer (Li et al. 2007). Its relatively flat landscape of behavioral risk factors, together with its medical preventability, make mortality from prostate cancer a purer indicator of health system performance than mortality from many other chronic diseases of adulthood.

## A. Prostate Cancer Screening

The Digital Rectal Examination (DRE) and Prostate Specific Antigen (PSA) test are the primary screening tools for prostate cancer. As a screening test, DRE is of limited value because it cannot investigate the entire prostate gland (Ilic et al. 2006). It is more difficult to detect cancer with DRE than with the PSA test (Harris and Lohr 2002). The PSA test has the added benefits of being easy to perform, relatively inexpensive, and reproducible (Constantinou 2006).

The PSA blood test for the presence of prostate cancer was approved by the Food and Drug Administration in 1986 (Shampo 2002). The test enables the detection of high and/or
rapidly increasing levels of an antigen that often signals the presence of prostate cancer. High levels of the antigen can also be produced by other conditions; confirmation of cancer is made by transrectal ultrasound-guided biopsy (TRUS).

The PSA test is somewhat controversial. One reason is that, like many other medical screens, the PSA test can produce a false positive - a report of potential cancer when it is not present. According to a summary of studies of the sensitivity and specificity of PSA testing, an average of $75 \%$ of those with PSA readings above $4.0 \mathrm{ug} / \mathrm{l}$ have prostate cancer and $71 \%$ of men with prostate cancer have a PSA reading above $4.0 \mathrm{ug} / \mathrm{l}$ (Bunting 2002). However, the main reservation about the use of the PSA test is that treatment for prostate cancer can produce impotence and/or incontinence. Because of these side effects, several organizations have recommended against PSA testing for men over 75 (U.S. Preventive Services Task Force 2008). On the other hand, the American Cancer Society and the American Urological Association recommend that the PSA test should be offered annually to men over 50 with at least a 10-year life expectancy.

By reputation the US has been the world leader in PSA testing, especially in the early years after the test was developed (Hsing, Tsao, and Devesa 2000; Levi et al. 2000; Vercelli et al. 200; De Koning et al. 2002; Bouchardy et al. 2008). Table 2 compiles the latest data that we were able to locate on the frequency of PSA testing in various countries or regions. The age ranges used and the survey dates are not identical from country to country, preventing exact comparisons. The United States has the highest recorded percentage ever tested at older ages (prevalence) as well as the highest percentage tested in a recent period (incidence). ${ }^{6}$

Evidence about the efficacy of PSA testing from randomized controlled trials has been mixed. The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial began in 1993 and involved 76,693 US men aged 55-74. After 7 to 10 years of follow up, the death rate from prostate cancer did not differ significantly between the study and control group. As noted by the authors, one possible explanation of the negative result is that PSA testing is already so frequent in the US (see Table 2) that high levels of screening were already present among the control group. Furthermore, many cancers had already been identified in both treatment and control groups (Andriole et al. 2009). Results of the study are most reasonably interpreted as

[^6]addressing the question of whether mortality advantages would pertain to extending PSA testing in a population in which half of men are already being tested every two years.

The second trial, the European Randomized Study of Screening for Prostate Cancer, was more than twice as large and was conducted in a region where prostate cancer screening is much less common. The trial began in the early 1990's in 7 European countries and included a total of 162,243 men between the ages of 55 and 69 . The study found that offering PSA screening to the treatment group reduced the death rate from prostate cancer by $20 \%$ (rate ratio of $0.73,95 \% \mathrm{CI}$, 0.56 to 0.90 ). The absolute reduction was 0.71 prostate-cancer deaths per 1,000 men. The median and average follow up times were 9 and 8.8 years, respectively; death rates in the two study groups began diverging after 7 to 8 years and continued to diverge subsequently (Schröder et al. 2009).

The Goteborg, Sweden component of the European trial followed 20,000 randomly selected men aged 50-66 for 10 years. Half were invited for biennial PSA testing, with 10,000 men serving as passive controls for whom diagnosis of metastatic prostate cancer was monitored by using the Swedish Cancer Registry. The risk of being diagnosed with metastatic, i.e., advanced, prostate cancer was reduced by $48.9 \%$ in the PSA treatment group relative to controls ( $\mathrm{p}<.01$ ) (Aus et al. 2007).

According to SEER, after the PSA test was introduced in the late 1980s, the recorded incidence of prostate cancer in the US rose from 119/100,000 in 1986 to a peak of 237/100,000 in 1992 (SEER 2008). ${ }^{7}$ The proportion of tumors that are metastatic was $25 \%$ of newlydiagnosed tumors in 1980 and only $4 \%$ in 2002 (Etzioni et al. 2008). Consistent with more extensive screening, the United States identifies prostate cancer at an earlier stage, on average, than Sweden (Stattin et al. 2005), Japan (Ogawa et al. 2008), or the United Kingdom (Collin et al. 2008). Stage at diagnosis is particularly important in prognosis - if detected at an early stage, prostate cancer can be treated by radical prostatectomy or radiotherapy.

## B. Prostate Cancer Treatment

Once prostate cancer is detected, a variety of treatments can be employed, including radical prostatectomy, radiation by beam (external beam radiotherapy) or implanted seeds (brachytherapy), or hormone therapy. "Watchful waiting" is also an option. Since 1991, radical

[^7]prostatectomy has been the most common treatment for localized prostate cancer in the US. It serves as the initial treatment for over a third of newly-diagnosed patients (Harris and Lohr 2002). Observational studies have described apparent survival advantages from radical prostatectomy and radiation therapy (e.g., Wong et al. 2006; Trock et al. 2008) but not always from hormone therapy alone (Lu-Yao et al. 2008). The questions of possible selection bias that are always present in observational studies add uncertainty to these results.

Uncertainty has been reduced by several recent reports of randomized clinical trials. A key study of Scandinavian men examined survival after diagnosis of prostate cancer. Men were randomly assigned to radical prostatectomy or to watchful waiting (Bill-Axelson et al. 2005). Some of those assigned to prostatectomy did not have the operation, and some of those assigned to watchful waiting pursued radiation or hormonal therapy. Nevertheless, after a median followup period of 8.2 years, the group assigned to prostatectomy had cumulative proportions dead from prostate cancer that were lower by $44 \%$, rates of disease progression that were lower by $67 \%$, and rates of distant metastasis that were lower by $40 \%$. All comparisons were statistically significant (Ibid.).

A randomized trial of variation in radiation dosage reported a highly significant beneficial effect on survival of heavier doses (Pollack et al. 2002). Another randomized trial of adjuvant radiotherapy enrolled 425 men with pathologically advanced prostate cancer who had undergone radical prostatectomy between 1988 and 1997. Adjuvant radiotherapy significantly reduced the risk of PSA relapse and disease recurrence, although improvements in survival were not statistically significant (Thompson et al. 2006).

Several randomized clinical trials evaluate the use of hormone therapy as an adjunct to surgery or radiation in high risk patients; the value of hormone therapy used alone or as primary therapy has only been assessed by observational studies. A population-based cohort study found that primary androgen deprivation therapy does not improve survival in elderly men compared with conservative management (no surgery, radiation, or hormone therapy) (Lu-Yao et al. 2008). However, three phase III randomized trials have shown that a combination of radiotherapy and androgen suppression improve survival relative to radiotherapy alone (Bolla et al. 2002, Hanks et al. 2003, and Pilepich et al. 2005).

Population-based information about the frequency of various treatments of prostate cancer is much skimpier than information about the use of the PSA test. Among US men aged

65-80 in SEER who were diagnosed with low grade tumors between 1991 and 1999, 25.5\% received no treatment within six months of diagnosis, $9.6 \%$ received hormone therapy, and the remaining $64.8 \%$ received either radiation or prostatectomy (Wong et al. 2006).

Scandinavian countries rarely use radical therapies - radical prostatectomy or radiation and rely primarily on watchful waiting or hormone therapy for palliation (Fleshner, Rakovitch, and Klotz 2000; Sandblom et al. 2000). For example, the fraction of patients treated with curative intent in Norway was only $3 \%$ in 1985-1989 and rose to $6 \%$ in 1990-1994. In 19901994, radical prostatectomy was used to treat only 3.0 and $3.3 \%$ of all patients diagnosed with prostate cancer in Norway and Sweden, respectively (Kvåle et al. 2007). Low levels of surgery and radiation therapy are also reported in Japan (Ogawa et al. 2008).

Differences in treatment approach also exist between the US and the UK, with US approaches generally being more aggressive, particularly in the use of surgery (Collin et al. 2008). A survey of American and Canadian urologists indicated that American urologists tended to have a more aggressive approach to case identification and surgical intervention. They were also more likely to perform radical prostatectomy on patients over the age of 70 (Fleshner, Rakovitch, and Klotz 2000).

## C. Prostate Cancer Survival

The combination of earlier detection and aggressive treatment in the US has produced greatly improved survival chances for men diagnosed with prostate cancer. 5-year relative survival rates in the US increased from $71 \%$ to $83 \%$ between 1984-86 and 1987-89, whereas European rates improved from $55 \%$ to $59 \%$ during the same period (Post et al. 1998). According to SEER (2008), the US 5-year relative survival rate had increased to $99.2 \%$ for those diagnosed in 2000.

Gatta et al. (2000) compared international survival rates for cancers diagnosed between 1985 and 1989. All of the European countries considered had lower prostate cancer survival rates than the US. European patients had a 4.1 times greater risk of dying in the first year after diagnosis, suggesting that earlier diagnosis plays an important role in these survival differences (Ibid.). The updated study whose results are presented in Table 1 found that 5-year survival rates for prostate cancer in 2000-02 were $99.3 \%$ in the US compared to $77.5 \%$ in Europe.

## D. Prostate Cancer Mortality

Population-level data on mortality have one distinct advantage over data on survival rates among those newly diagnosed: they are not subject to lead-time bias. If one country is diagnosing cancer sooner than another but early diagnosis does not alter the clinical course of the disease and delay or prevent death, then that country will enjoy no advantage in mortality as a result of its earlier diagnoses. When early diagnosis improves prognosis, population-level mortality is responsive to the timeliness of diagnosis. It is also responsive to the efficacy of treatments employed regardless of stage at diagnosis. Mortality data has a similar advantage relative to recorded incidence and prevalence data, both of which are subject to lead-time bias.

In order to investigate whether the relatively aggressive use of PSA testing and therapy in the United States has produced an unusually rapid decline in mortality from prostate cancer, we have used World Health Organization data on deaths by cause and population by five-year age groups. We have chosen a group of 15 economically developed OECD countries for purposes of comparison: Australia, Austria, Canada, Finland, France, Germany, Greece, Italy, Japan, the Netherlands, Norway, Spain, Sweden, Switzerland, and United Kingdom.

Figure 3 compares levels of age-standardized death rates per 100,000 (all ages combined) in the United States to the unweighted mean death rate in these 15 comparison countries. ${ }^{8}$ With the exception of 1985, the US had higher deaths rates each year from 1980 to 1995. Beginning in 1996, the US had lower rates and the US advantage grew every year thereafter. By 2003, the US had death rates that were $20.4 \%$ lower than the mean of the comparison countries. Mortality rates among men 60-79 were lower in 1997 than in any year since 1950 (Tarone, Chu, and Brawley 2000). Baade, Coory, and Aitken (2004) note that changes in risk factors and in the accuracy of or procedures for recording cause-of-death information are unlikely to be responsible for the observed trends.

Declines in prostate cancer mortality have been attributed to both PSA screening and improvements in treatment (Baade et al. 2004; Potosky, Feuer, and Levin 2001; Bouchardy et al. (2008), Kvåle et al. (2007), Collin et al. (2008).) An individual-level population model that used counterfactuals to simulate US mortality and incidence of advanced-stage prostate cancer concluded that two-thirds of the decline in mortality between 1990 and 1999, and $80 \%$ of the

[^8]decline in distant-stage incidence, was attributable to expanded PSA testing (Etzioni et al. 2008).
To test whether the faster mortality decline in the US was statistically significant, we use a negative binomial regression in a fixed-effects model applied to data for these 16 countries for the period 1982 to 2005 . The dependent variable is the $\log$ of the number of deaths from prostate cancer in a particular age, country and year cell, with population size in a particular cell used as the exposure. Independent variables are a set of age group identifiers, a set of period identifiers, a dummy variable for the US, and a set of US/period interactions. Six 4-year-wide time periods are used, beginning with 1982-85 and ending with 2002-05. 1982-1985, the period before PSA testing was begun, is chosen as the reference period. Significance tests recognize the clustering of observations by country. Results are presented in Table 4.

The coefficient of the interactive variable for US observations during the period 2002-05 is -0.274 , which is significant at $\mathrm{p}<.001$. Compared to expectations based upon country and year, the US had roughly $27 \%$ lower mortality in 2002-05 than it did in 1982-85. (The US/20022005 variable is always significant at $\mathrm{p}<0.001$ regardless of reference period used). Likewise, the coefficient of the US/period interactive variable for the 1998-2001 period is -0.215 and is also significant at $\mathrm{p}<.001$. So the US had significantly faster declines in mortality than did comparison countries between 1982-85 and both 1998-2001 and 2002-05.

Mortality trends from prostate cancer may be affected by "attribution bias": people who have had prostate cancer detected may be more likely to have their death ascribed to it even though some other morbid process were actually responsible (Feuer et al. 1999). Such bias, combined with more aggressive screening, would produce a rise rather than a fall in prostate cancer mortality. This bias may account for the rise in prostate cancer mortality in the late 80 s and early 90 s (Figure 3), but it obviously would minimize rather than accentuate the actual decline that is observed between 1982-85 and 2002-05.

African Americans have prostate cancer death rates that are among the highest in the world (Crawford 2003). Perhaps the most prominent explanation of the racial disparity is that dark skin inhibits the absorption of Vitamin D, which is highly protective against prostate cancer (Li et al. 2007). A more tenuous connection to the health care system among African Americans is probably also a factor. Nevertheless, a sharp decline in prostate cancer mortality in the US is evident among both whites and African Americans. Both whites and blacks had rates that peaked in the early 1990s. Between $1992 / 3$ and 2004/5, the death rate declined by $32.2 \%$ for African

Americans and by $36.3 \%$ for whites (Ibid.). The absolute decline in rates was much larger for African Americans. The 5-year survival rate for blacks increased from $68.4 \%$ for those diagnosed in 1986, the year when PSA testing was approved, to $97.0 \%$ for those diagnosed in 2000. Among whites, the improvement was from $79.0 \%$ to $99.8 \%$ (SEER 2008).

## Case Study II. Breast Cancer

Breast cancer is the most common cause of cancer death among women in a majority of high income countries (Vainio and Bianchini 2002). In contrast to prostate cancer, there are important behavioral risk factors for breast cancer. These include childlessness or low parity, late age at first birth, obesity, and use of hormone replacement therapy (Das et al. 2005; Levi et al. 2005). Thus, trends in mortality are more difficult to interpret as exclusively reflecting medical factors. But, like prostate cancer, breast cancer is highly amenable to medical intervention through screening and therapy.

## A. Breast Cancer Screening

Mammography, breast self-examination, clinical breast examination (CBE), and magnetic resonance imaging (MRI) are used to screen for breast cancer. No randomized trials of CBE alone have been completed, and case-control and ecological studies have provided only limited evidence for its efficacy in reducing mortality from breast cancer (Vainio and Bianchini 2002). Breast self-examination is an appealing screening method because it is noninvasive, but it has weak ability to detect breast cancer (Elmore et al. 2005). Two randomized trials of breast self-examination have been conducted, and neither found evidence of mortality reduction. The International Agency for Research on Cancer (IARC) has concluded that there is inadequate evidence for the efficacy of CBE and breast self-examination in reducing breast cancer mortality (Vainio and Bianchini 2002). The US Preventive Services Task Force also found evidence from trials involving CBE and breast self-examination to be inconclusive (Humphrey et al. 2002). The third technique, MRI, is mainly employed in high risk patients and after conventional diagnostic procedures have already been conducted (Veronesi et al. 2005). Because of its high cost (approximately 10 times that of mammography) and its relatively low specificity, MRI is not a feasible tool for routine screening in the general population (Elmore et al. 2005).

Thus, mammography is currently the most important diagnostic tool for breast cancer. It
is the only screening test that has been shown to reduce mortality from breast cancer in randomized trials and population studies (Veronesi et al. 2005; Wells 1998). The International Agency for Research on Cancer (IARC) concluded that there is sufficient evidence from randomized trials that offering of mammography to a treatment group reduces breast cancer mortality in women aged $50-69$, by an average of $25 \%$. After adjusting for the effect of nonacceptance of the screening invitation, this figure rises to $35 \%$ (Vainio and Bianchini 2002). The US Preventive Services Task Force reviewed eight randomized controlled trials of offering mammograms to treatment groups and concluded that, for studies of that were designated as of fair quality or better, the relative mortality risk for women aged $40-74$ was $0.84(95 \% \mathrm{CI}, 0.77$ to 0.91 ) (Humphrey et al. 2002; see also Gøtzsche and Nielsen 2009). While some concerns have been raised concerning flaws in the trials' design and execution, in-depth independent reviews have concluded that they do not negate the trials' results (Quinn 2003).

The National Cancer Institute and the American Cancer Society (ACS) issued the first formal guidelines for mammography in 1977, advocating screening for all women over the age of 50 (Wells 1998). Currently, all major US medical organizations recommend screening mammography for women over the age of 40 (Elmore et al. 2005; Ahern and Shen 2009). The US is the only country that strongly endorses screening mammography for women under age 50 (Jatoi and Miller 2003); recent evidence has supported the efficacy of screening in the age group 40-49 (Humphrey et al. 2002).

Use of mammographic screening in the United States increased very rapidly; the percentage of women aged 50-64 who reported having a mammogram in the past 2 years increased from $31.7 \%$ in 1987 to $73.7 \%$ in 1998 (Breen et al. 2001). Screening programs generally began later in Europe than in the US (Møller et al. 2005). The start dates for organized screening programs in the countries under investigation range from 1986 to 1999 (Shapiro et al. 1998; Jatoi and Miller 2003).

Table 3 presents international data on the frequency of screening for breast cancer in recent years. In the early-to-mid 90s, the United States had the highest frequency of mammograms in the nine countries for which we are able to locate data. The OECD has collected more recent data which shows that, while the frequency of mammograms has increased in the US, it has grown faster in a number of other countries. Of the 19 countries shown in Table 2, the United States ranks $6^{\text {th }}$ in the proportion of women in or around the age interval 50-69 who
had received mammograms in the previous two years.
Consistent with the relatively high frequency of mammograms in the US, Sant et al. (2004) found that breast cancer is diagnosed at what is, on average, a later stage in Europe than in the US.

## B. Breast Cancer Treatment

In OECD countries, the large majority of cases of breast cancer are treated surgically. Surgery is often supplemented with some combination of radiotherapy, hormone therapy, and chemotherapy (i.e., adjuvant therapy). Descriptions of the Halsted mastectomy, which served as the treatment of choice for breast cancer for almost a century, were first published in 1894 (Veronesi et al. 2002). It was later replaced by the modified radical mastectomy, which was popular in the 1980s (Cotlar et al. 2003). Neither the original Halsted radical mastectomy nor the modified radical mastectomy were introduced on the basis of evidence from randomized clinical trials; however, observational studies confirm an enormous survival advantage for surgery relative to no surgery (e.g., Sant et al. 2004).

In most high income countries, breast conserving surgery (BCS, also known as lumpectomy) is currently the most common primary treatment for breast cancer (Veronesi et al. 2005). Relative to total mastectomy, its advantages are reduced disfigurement and morbidity rather than mortality (Wood 1994). After 20 years of follow-up in a randomized trial, Fisher et al. (2002) report finding no differences in disease-free survival, distant-disease-free survival, or overall survival between women who underwent lumpectomy alone compared to those having a total mastectomy (see also Veronesi et al. 2002). In 1990, the National Institutes of Health Consensus Development Conference recommended breast conservation therapy for the majority of women with Stage I or II breast carcinoma.

Radiation treatment of breast cancer was first used in 1896, but equipment and techniques have improved substantially, particularly since the 1960s (Ragaz et al. 1997). The Early Breast Cancer Trialists' Collaborative Group conducted a meta-analysis of 36 trials of radiotherapy. They found that the local recurrence rate with radiotherapy and surgery was three times lower than with surgery alone, and that radiotherapy was associated with $6 \%$ reduction in the relative risk of death due to breast cancer (odds ratio, 0.94) (Early Breast Cancer Trialists' Collaborative Group 1995). Ragaz et al. (1997) found that, after 15 years of follow-up, women assigned to
chemotherapy plus radiotherapy had a $33 \%$ reduction in the recurrence rate and a $29 \%$ reduction in mortality from breast cancer compared to women treated with chemotherapy alone.

Adjuvant systemic multi-agent chemotherapy and tamoxifen have been estimated to reduce mortality (in terms of the relative reduction of the annual odds of death) by $27 \%$ and 47\%, respectively (Early Breast Cancer Trialists’ Collaborative Group 1998a, 1998b). These figures are derived from the meta-analyses of all randomized trials of any aspect of treatment for early breast cancer that began before 1990. There were 47 trials of adjuvant polychemotherapy involving 18,000 women (Early Breast Cancer Trialists’ Collaborative Group 1998a). Greater benefits were reported in women under the age of 50 , who experienced with significant reductions in recurrence and mortality of $35 \%$ and $27 \%$. For women between 50 and 69 , these figures were $20 \%$ and $11 \%$ (Ibid.).

Cole et al. first reported the clinical efficacy of tamoxifen for disseminated breast cancer in 1971. The Early Breast Cancer Trialists' Collaborative Group summarized the results of 55 randomized controlled trials involving more than 37,000 women. Compared to a placebo, adjuvant tamoxifen resulted in annual reductions of $26 \%$ in recurrence and $14 \%$ in death. Among women treated for five years, these figures rose to $50 \%$ and $28 \%$, respectively (Early Breast Cancer Trialists' Collaborative Group 1998b; Osborne 1998) Tamoxifen produces significant benefits in women of all age groups (Jaiyesimi et al. 1995; Early Breast Cancer Trialists' Collaborative Group 1998b). Following pharmacologic and clinical evaluations, the US Food and Drug Administration approved tamoxifen for the treatment of metastatic breast cancer in postmenopausal women in 1977. Tamoxifen was also approved as the initial endocrine therapy for disseminated breast cancer in premenopausal women.

Information on international differences in breast cancer treatment is limited. A comparison of the Eurocare and SEER registry data found that $97 \%$ of women in SEER were treated surgically compared to $90 \%$ in the Eurocare registries. Lymphadenectomy rates were slightly more extensive in the US, and more axillary lymph nodes were examined in the US (Sant et al. 2004). Hughes (2003) compared patterns of breast cancer care in Belgium, Canada (Manitoba and Ontario), France, Italy, Norway, Sweden, United Kingdom (England), and the United States. During the latest period investigated, 1990-93, at least $90 \%$ of women diagnosed with breast cancer received a mastectomy or breast-conserving surgery in all areas except Ontario, where the figure was $82 \%$, and England (71\%). The use of radiotherapy with BCS has
also risen over time and varied considerably among countries. Among women receiving BCS in 1995-97, Belgium, France, Canada and the UK had the highest proportions of women receiving radiation therapy. The US ranked below these countries and above Sweden and Italy (Ibid.)

Adjuvant chemotherapy became standard treatment for breast cancer patients in the US in the late 1970s (Ragaz et al. 1997). Tamoxifen began to be widely used in the late 1970s and early 1980s after the Nolvadex Adjuvant Trial Organization trials demonstrated its effectiveness (Mariotto et al. 2002). It has since become the most widely prescribed antineoplastic agent for treatment of breast cancer in the United States and Great Britain (Jaiyesimi et al. 1995). Between 1975 and 2000, the percentage of breast cancer patients receiving chemotherapy in the US increased from essentially 0 to $80 \%$, while tamoxifen use increased from 0 to $50 \%$ (Berry et al. 2006). Starting in the mid-1980s, tamoxifen use in the UK also increased rapidly. By 1990, $50 \%$ of women with breast cancer over the age of 50 in the Thames region were receiving tamoxifen (Blanks et al. 2000). Unfortunately, we have not found comparable international data on the use of chemotherapy and tamoxifen. Variations in stage and type of tumor, age of patient, type of surgery, and other factors make it impossible to reliably compare the few national or regional data that exist.

## C. Breast Cancer Survival

Several studies have compared international survival rates from breast cancer. As noted above, the survival advantage of US breast cancer patients compared to their European counterparts is well documented. The US survival advantage is particularly sharp among older women (Hughes 2003). International differences in survival are challenging to interpret, but three studies using cancer registry data for European and American women cancer survival have attributed the survival differences from breast cancer to earlier diagnosis and more aggressive care in the US. These factors have also been introduced to explain better breast cancer survival rates in the US than in Canada (Ugnat et al. 2005).

Gatta et al. (2002) found that European breast cancer patients diagnosed 1985-89 had significantly lower five-year relative survival rates than American patients ( $73 \%$ vs. $82 \%$ ). None of the 17 European countries had higher five-year relative survival than the US. In the first year after diagnosis, the risk of death from breast cancer was much higher in European than American patients. Survival rates fell with increasing age at diagnosis in both the US and Europe, but the
fall was more marked in Europe. Gatta et al. suggest that the survival rate differences may be attributable to earlier diagnosis in the US.

The most thorough study compared American and European women diagnosed with breast cancer between 1990 and 1992 (Sant et al. 2004). The five-year survival rate was higher in the US than in Europe ( $89 \%$ vs. $79 \%$ ), and survival for each stage-at-diagnosis category was also higher in the US. Early-stage tumors were more frequent in the US ( $41 \%$ of cases) than in Europe (29\%). Treatment was more aggressive in the US, where $97.1 \%$ of women underwent surgery compared to $90.2 \%$ in Europe. In the US, $50.7 \%$ of women had $15+$ lymph nodes evaluated for metastasis, compared to $27.8 \%$ in Europe. The overall relative risk of death was $37 \%$ higher among European women ( $95 \%$ confidence interval $25-50 \%$ ). The excess risk was reduced to $20 \%$ by adjustment for surgical intervention, which was associated with a $90 \%$ reduction in mortality. Adjustment for stage at diagnosis reduced the relative risk to $12 \%$ and further adjustment for the number of lymph nodes evaluated to determine cancer progression reduced the excess risk of death among the European women to an insignificant 7\%. Introducing information on the use of radiotherapy did not alter the relative risk of European women. Thus, the higher survival rate in the US appears to be a result both of earlier diagnosis and more aggressive treatment.

The most recent study compared cancer survival differences between Europe and the US in 2000-2002 based on period rather than cohort survival data. As shown in Table 1, the fiveyear survival rate for breast cancer was $79.0 \%$ in Europe, compared with $90.1 \%$ in the US. Verdecchia et al. (2007) hypothesize that these differences were most likely due to differences in timeliness of diagnosis.

Trends in screening and in survival in the US are consistent with the idea that earlier screening improves survival. The increase in the percentage of American women aged 50-64 with a mammogram in the previous two years from $32 \%$ in 1987 to $74 \%$ in 1998 was accompanied by an increase in five-year survival rates from $79 \%$ for those diagnosed in 1985 to $91 \%$ for those diagnosed in 2000 (SEER 2008).

## D. Breast Cancer Mortality

In many developed countries, breast cancer mortality rates began declining around 1990 (Veronesi et al. 2005; Botha et al. 2003). It is unlikely that the declines in mortality were caused
by changes in the major risk factors for the disease. In fact, the risk factor profile of women in high income countries has, if anything, become less favorable over the past few decades as a result of rising obesity and delayed and reduced childbearing (Levi et al. 2005). Reductions after 2002 in the use of hormone replacement therapy could work in the opposite direction but the risk is sufficiently small (Writing Group for the Women's Health Initiative Investigators 2002; Chlebowski et al 2003), and lags sufficiently long, that the decline should not be reflected in a data series that ends in 2005. Chu et al. (1996) rule out changes in coding or ascertainment as contributors to the mortality decline in the US, noting that there had been no coding changes affecting breast cancer and that no systematic problems with ascertainment were identified after 1989.

Studies of trends in breast cancer mortality have attributed the declines mainly to earlier detection - in particular, rising rates of mammographic screening - and improved treatment (Veronesi et al. 2005; Levi et al. 2005; Chu et al. 1996). A careful, detailed simulation for the US by Berry et al. (2006) concluded that "We can say with high probability that both screening and adjuvant therapy have contributed to the reductions in U.S. breast cancer mortality observed from 1975 (and especially from 1990) to 2000. Our best estimate is that about two-thirds of the reduction is due to therapy and one-third to screening" (Berry et al. 2006:36). Using less precise methods, Blanks et al. (2000) reached a similar conclusion about the decline in breast cancer mortality in England and Wales from 1990 to 1998. Evidence that states with greater use of mammography had greater mortality declines between 1992 and 1999 supports the link between screening and mortality (Das et al. 2005).

We hypothesize that the US has had a faster decline in breast cancer mortality than the comparison countries because it took better advantage of technological advances in screening and treatment. Mortality data alone do not permit us to distinguish between the effects of screening and treatment, but that distinction is not central to judging the effectiveness of a health care system.

Figure 4 shows the annual age-standardized death rate in the United States and the average for our 15 OECD countries since 1980. Clearly, the US has had a faster decline in breast cancer mortality than average among the comparison countries. Is the faster decline in the US statistically significant? To answer this question, we repeat the approach used for prostate cancer, using WHO data files on deaths by cause and population by five-year age groups. We
employ negative binomial regression on data at ages 50+ (in five-year wide age groups until $85+$ ). The dependent variable is the log of the number of deaths from breast cancer in a certain age group for a particular country and time period. Independent variables are a set of age group identifiers, a set of period identifiers, a dummy variable for the US, and a set of US/period interactions. We designate six 4-year-wide time periods, beginning with 1982-85 and ending with 2002-05, and choose 1982-85 as the reference period. Because of the rapid increase in the proportion of women receiving mammograms from less than a third in 1987 to $74 \%$ in 1998, a reference period in the early 1980s appears appropriate. Significance tests recognize the clustering of observations by country. Results are presented in Table 4.

Using 1982-85 as the reference period, we find that the US/2002-05 interaction term is significant at .01. With a coefficient of -.126 , the coefficient implies that mortality in the US has fallen $13 \%$ faster since 1982-85 than in other countries. US interactive coefficients for 1994-97 and 1998-2001 are also negative and significant at 5\%. The interactive variable, US/2002-2005, is always significant at $\mathrm{p}<0.01$ regardless of which date is selected as reference period (not shown). Thus, the US has experienced a significantly faster decline in breast cancer mortality than comparison countries.

## Summary

We have demonstrated that mortality reductions from prostate cancer and breast cancer have been exceptionally rapid in the United States relative to a set of peer countries. We have argued that these unusually rapid declines are attributable to wider screening and more aggressive treatment of these diseases in the US. It appears that the US medical care system has worked effectively to reduce mortality from these important causes of death.

This conclusion is consistent with other evidence that we have reviewed on the performance of the US health care system: screening for other cancers also appears unusually extensive; 5-year survival rates from all of the major cancers are very favorable; survival rates following heart attack and stroke are also favorable (although one-year survival rates following stroke are not above average); the proportion of people with elevated blood pressure or cholesterol levels who are receiving medication is well above European standards.

These performance indicators pertain primarily to what happens after a disease has developed. It is possible that the US health care system performs poorly in preventing disease in
the first place. Unfortunately, there are no satisfactory international comparisons of disease incidence. Individuals report a higher prevalence of cancer and cardiovascular disease in the United States than in Europe, and biomarkers confirm the higher prevalence of many disease syndromes in the US compared to England and Wales. Higher disease prevalence is prima facie evidence of higher disease incidence, although it could also be produced by better identification (e.g., through screening programs) or better survival. The history of exceptionally heavy smoking in the US, and the more recent massive increase in obesity, suggest that a high disease incidence in the US could not be laid entirely at the feet of the health care system.

Evidence that the major diseases are effectively diagnosed and treated in the US does not mean that there may not be great inefficiencies in the US health care system. A list of prominent charges include fragmentation, duplication, inaccessibility of records, the practice of defensive medicine, misalignment of physician and patient incentives, limitations of access for a large fraction of the population, and excessively fast adoption of unproven technologies (Garber and Skinner, 2008; Cebul et al. 2008; Commonwealth Fund 2008). Some of these inefficiencies have been identified by comparing performance across regions of the United States. Of course, the fact that certain regions do poorly relative to others does not imply that the US does poorly relative to other countries. And many of the documented inefficiencies of the US health care system add to its costs rather than harm patients.

Just as we are not addressing issues of efficiency on the production side, we are not treating patient welfare as the main outcome. Practices that produce greater longevity do not necessarily enhance well-being. This potential disparity is central to the controversy involving PSA testing, which uncovers many cancers that would never kill patients but whose treatment often produces adverse side effects.

The question that we have posed is much simpler: does a poor performance by the US health care system account for the low international ranking of longevity in the US? Our answer is, "no".

## References

Ahern, Charlotte Hsieh and Yu Shen. 2009. "Cost-Effectiveness Analysis of Mammography and Clinical Breast Examination Strategies: A Comparison with Current Guidelines." Cancer Epidemiol Biomarkers Prev Vol. 18(3): 718-25.
Anderson, Gerald F. and Bianca K. Frogner. 2008. "Health Spending in OECD Countries: Obtaining Value Per dollar." Health Affairs Vol. 27(6): 1718-1727.
Andriole, Gerald L., Robert L. Grubb, Saundra S. Buys, David Chia, et al. 2009. "Mortality Results from a Randomized Prostate-Cancer Screening Trial." New England Journal of Medicine Vol. 360: 1310-19.
Aus, Gunnar, Svante Bergdahl, Pär Lodding, Hans Lilja, et al. 2007. "Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate CancerResults from a Prospective, Population-Based Randomized Controlled Trial." European Urology Vol. 51: 659-664.
Avendano, Mauricio, Maria Glymour, James Banks, and Johan P. Mackenbach. 2009. "Health Disadvantage in US Adults Ages 50 to 74 Years: A Comparison of the Health of Rich and Poor Americans with That of Europeans." American Journal of Public Health Vol. 99(3): 540-548.
Baade, P.D., M.D. Coory, and J.F. Aitken. 2004. "International Trends in Prostate-Cancer Mortality: The Decrease Is Continuing and Spreading." Cancer Causes \& Control Vol. 15(3): 237-241.
Banks, James, Michael Marmot, Zoe Oldfield, and James P. Smith. 2006. "Disease and Disadvantage in the United States and in England." Journal of the American Medical Association Vol. 295(17): 2037-2045.
Berry, Donald A., Kathleen A. Cronin, Sylvia K. Plevritis, Dennis G. Fryback, et al. 2005. "Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer." New England Journal of Medicine Vol. 353: 1784-92.
Berry, Donald A., Lurdes Inoue, Yu Shen, John Venier, et al. 2006. "Modeling the Impact of Treatment and Screening on U.S. Breast Cancer Mortality: A Bayesian Approach." Journal of the National Cancer Institute Monograph Vol. 36: 30-36.
Bill-Axelson, A., L. Holmberg, M. Ruutu, M. Haggman, S Andersson, S. Bratell, A. Spangberg, C. Busch, S. Nordling, H. Garmo, J. Palmgren, H. Adami, B. Norlen, and J. Johansson, 2005. "Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer." New England Journal of Medicine. Vol. 352(19): 1977-84.
Blanks, R.G., S.M. Moss, C.E. McGahan, M.J. Quinn, et al. 2000. "Effect of NHS Breast Screening Programme on Mortality from Breast Cancer in England and Wales, 1990-8: Comparison of Observed with Predicted Mortality." British Medical Journal Vol. 321: 665-669.
Bolla, Michael, Laurence Collette, Léo Blank, Padraig Warde, et al. 2002. "Long-term Results with Immediate Androgen Suppression and External Irradiation in Patients with Locally Advanced Prostate Cancer (an EORTC Study): a Phase III Randomised Trial." Lancet Vol. 360(9327): 103-8.
Botha, J.L., F. Bray, R. Sankila, and D.M. Parkin. 2003. "Breast cancer Incidence and Mortality Trends in 16 European Countries." European Journal of Cancer Vol. 39: 1718-1729.
Bouchardy, Christine, Gerald Fioretta, Elisabetta Rapiti, Helena Maria Verkooijen, et al. 2008. "Recent Trends in Prostate Cancer Mortality Show a Continuous Decrease in Several

Countries." International Journal of Cancer. Vol. 123: 421-429.
Breen, Nancy, Diane K. Wagener, Martin L. Brown, William W. Davis, et al. 2001. "Progress in Cancer Screening Over a Decade: Results of Cancer Screening From the 1987, 1992, and 1998 National Health Interview Surveys." J Natl Cancer Inst Vol. 93(22): 1704-13.
Bunting, P. 2002. "Screening for Prostate Cancer with Prostate-specific Antigen: Beware the Biases." Clinica Chimica Acta Vol. 315: 71-97.
Cebul, R.D., J.B. Rebitzer, L.J. Taylor, and M.E. Votruba. 2008. "Organizational Fragmentation and Care Quality in the U.S. Healthcare System." Journal of Economic Perspectives Vol. 22(4): 93-113.
Centers for Disease Control and Prevention. 2002. "Annual Smoking-Attributable Mortality, Years of Potential Life Lost, and Economic Costs- United States, 1995-1999." Morbidity and Mortality Weekly Report Vol 51(14): 300-303.
Chlebowski R.T., S.L. Hendrix, R.D. Langer, et al. 2003. "Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: the Women's Health Initiative Randomised Trial." Journal of the American Medical Association Vol. 289: 3243-53.
Chu, Kenneth C., Robert E. Tarone, Larry G. Kessler, Lynn A. G.Ries, et al. 1996. "Recent Trends in U.S. Breast Cancer Incidence, Survival, and Mortality Rates." Journal of the National Cancer Institute Vol. 88: 1571-9.
Ciccolallo, L., R. Capocaccia, M.P. Coleman, F. Berrino, et al. 2005. "Survival Differences Between European and US Patients with Colorectal Cancer: Role of Stage at Diagnosis and Surgery." Gut Vol. 54(2): 268-273.
Collin, Simon M., Richard M. Martin, Chris Metcalfe, David Gunnell, et al. 2008. "Prostatecancer Mortality in the USA and UK in 1975-2004: an Ecological Study." Lancet Oncology Vol. 9: 445-52.
Commonwealth Fund Commission on a High Performance Health System. 2008. Why Not the Best? Results from the National Scorecard on U.S. Health System Performance, 2008. Commonwealth Fund. New York.
Congressional Budget Office. 2007. The Long-Term Outlook for Health Care Spending: A CBO Study. CBO Publication No. 3085. U.S. Government Printing Office. Washington, DC.
Constantinou, J. and M.R. Fenely. 2006. "PSA Testing: an Evolving Relationship with Prostate Cancer Screening." Prostate Cancer and Prostatic Diseases Vol. 9: 6-13.
Cotlar, Alvin M., Joseph J. Dubose, and D. Michael Rose. 2003. "History of Surgery for Breast Cancer: Radical to the Sublime." Current Surgery Vol. 60(3): 329-337.
Crawford, E. David. 2003. "Epidemiology of Prostate Cancer." Urology Vol. 62 (6 suppl 1): 312.

Crimmins, Eileen, K. Garcia, and J.K. Kim. 2009. "Are International Differences and Trends in Life Expectancy in Sync with Differences and Trends in Health and/or Disability?" Forthcoming in Eileen Crimmins and Samuel Preston, Divergent Trends in Life Expectancy. National Research Council. Washington, D.C.
Cutler, David. 2004. Your Money or Your Life. Oxford University Press. New York.
Cutler, David M., Edward L. Glaeser, and Jesse M. Shapiro. 2003. "Why Have Americans Become More Obese?" Journal of Economic Perspectives. Vol. 17(3): 93-118.
Cutler, David M. and Edward L. Glaeser. 2006. "Why do Europeans Smoke More than Americans?" NBER Working Paper 12124.
Das, Barnali, Eric J. Feuer, and Angela Mariotto. 2005. "Geographic Association Between

Mammography Use and Mortality Reduction in the US." Cancer Causes and Control Vol. 16: 691-699.
De Koning Harry J., Michael K. Liem, Caroline A. Baan, Rob Boer, et al. 2002. "Prostate Cancer Mortality Reduction by Screening: Power and Time Frame with Complete Enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) Trial." International Journal of Cancer Vol. 98(2): 268-73.
DeNavas-Walt, Carmen, Bernadette D. Proctor, and Jessica Smith. 2007. Income, Poverty, and Health Insurance Coverage in the United States: 2006. U.S. Census Bureau, Current Population Reports, P60-233. U.S. Government Printing Office. Washington, DC.
Early Breast Cancer Trialists' Collaborative Group. 1995. "Effects of Radiotherapy and Surgery in Early Breast Cancer: An Overview of the Randomized Trials." New England Journal of Medicine Vol. 333(22): 1444-55.
Early Breast Cancer Trialists' Collaborative Group. 1998a. "Polychemotherapy for Early Breast Cancer: an Overview of the Randomised Trials." Lancet Vol. 352: 930-42.
Early Breast Cancer Trialists' Collaborative Group. 1998b. "Tamoxifen for Early Breast Cancer: an Overview of the Randomised trials." Lancet Vol. 351: 1451-1467.
Elmore, Joann G., Katrina Armstrong, Constance D. Lehman, and Suzanne W. Fletcher. 2005. "Screening for Breast Cancer." Journal of the American Medical Association Vol. 293: 1245-1256.
Etzioni, Ruth, R. Gulati, S. Falcon, and D. Penson. 2008. "Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in theUnited States: A Surveillance Modeling Approach: Medical Decision Making. Vol. 28: 323-331.
Fisher, Bernard, Stewart Anderson, John Bryant, Richard Margolese, et al. 2002. "Twenty-year Follow Up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy Plus Irradiation for the Treatment of Invasive Breast Cancer." New England Journal of Medicine Vol. 347(16): 1233-41.
Fleshner, Neil, Eileen Rakovitch, and Laurence Klotz. 2000. "Differences Between Urologists in the United States and Canada in the Approach to Prostate Cancer." Journal of Urology Vol. 163: 1461-466.
Forey, Barbara, J. Hamling, P. Lee, and N. Wald, editors. 2002. International Smoking Statistics: A Collection of Historical Data from 30 Economically Developed Countries. Oxford University Press. London.
Feuer, Eric J., R.M. Merrill, and B.F. Hankey. 1999. "Cancer Surveillance Series: Interpreting Trends in Prostate Cancer-Part II: Cause of Death Misclassification and the Recent Rise and Fall in Prostate Cancer Mortality." Journal of the National Cancer Institute. Vol. 91(12): 1025-32.
Garber, Alan. 2003. "Comparing Health Systems from the Disease-specific Perspective" pp. 95106 in Organisation for Economic Co-operation and Development. 2003. A DiseaseBased Comparison of Health Systems: What is Best and at What Cost? OECD. Paris.
Garber, Alan M. and Jonathan Skinner. 2008. "Is American Health Care Uniquely Inefficient?" Journal of Economic Perspectives Vol. 22(4): 27-50.
Gatta, Gemma, Riccardo Capocaccia, Michel P. Coleman, Lynn A. Gloeckler Ries, et al. 2000. "Toward a Comparison of Survival in American and European Cancer Patients." Cancer Vol. 89(4): 893-900.
Gøtzsche, P.C. and M. Nielsen. 2009. "Screening for Breast Cancer with Mammography (Review)." Cochrane Database of Systematic Reviews Issue 2: 1-90.

Haldorsen, Tor and Tom K. Grimsrud. 1999. "Cohort Analysis of Cigarette Smoking and Lung Cancer Incidence among Norwegian Women." International Journal of Epidemiology Vol. 28(6): 1032-1036.
Halliday, A., A. Mansfield, J. Marro, C. Peto, et al. 2004. "Prevention of Disabling and Fatal Strokes by Successful Carotid Endarterectomy in Patients Without Recent Neurological Symptoms: Randomised Controlled Trial." Lancet Vol. 363(9420): 1491-502.
Hanks, Gerald E., Thomas F. Pajak, Arthur Porter, David Grignon, et al. 2003. "Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92- 02." Journal of Clinical Oncology Vol. 21(21): 3972-3978.
Harris, Russell and Kathleen N. Lohr. 2002. "Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force." Annals of Internal Medicine Vol. 137(11): 917-29.
Hsing, Ann W., Lilian Tsao, and Susan S. Devesa. 2001. "International Trends and Patterns of Prostate Cancer Incidence and Mortality." International Journal of Cancer Vol. 85(1): 60-67.
Hughes, Melissa. 2003. "Summary of Results from Breast Cancer Disease Study" pp. 77-94 in Organisation for Economic Co-operation and Development. 2003. A Disease-Based Comparison of Health Systems: What is Best and at What Cost? OECD. Paris.
Humphrey, Linda L., Mark Helfand, Benjamin K.S. Chan, and Steven H. Woolf. 2002. "Breast Cancer Screening: A Summary of the Evidence for the U.S. Preventive Services Task Force." Annals of Internal Medicine Vol. 137(5,1): 347-360.
Ilic, Dragan, Denise O'Connor, Sally Green, and Timothy Wilt. 2006. "Screening for prostate cancer." Cochrane Database of Systematic Reviews Issue 3.
International Agency for Research on Cancer. 2008. Website presenting World Health Organization mortality data. Lyon, France. Accessed June-August 2008.
Institute of Medicine. 2001. Coverage Matters: Insurance and Health Care. National Academy Press. Washington, DC.
Jaiyesimi, Ishmael A., Aman U. Buzdar, David A. Decker, and Gabriel N. Hortobagyi. 1995. "Use of Tamoxifen for Breast Cancer: Twenty-Eight Years Later." Journal of Clinical Oncology Vol. 13:513-529.
Jatoi, Ismail, and Anthony B. Miller. 2003. "Why is Breast-Cancer Mortality Declining?" Lancet Oncology Vol. 4: 251-254.
Kapteyn, Arie, James P. Smith, and Arthur van Soest. 2007. "Vignettes and self-reports of work disability in the United States and the Netherlands." American Economic Review Vol. 97(1): 461-473.
Kaul, P., P. Armstrong, W. Chang, C. Naylor, C. Granger, K. Lee, I. Peterson, R. Califf, E. Topol, and D. Mark. 2004. "Long-term Mortality of Patients with Acute Myocardial Infarction in the United States and Canada." Circulation Vol. 110: 1754-60.
Kvåle, Rune, Anssi Auvinen, Hans-Olov Adami, Åsa Klint, et al. 2007. "Interpreting Trends in Prostate Cancer Incidence and Mortality in the Five Nordic Countries." Journal of the National Cancer Institute Vol. 99(24): 1881 - 7.
Levi, Fabio, Cristina Bosetti, Franca Lucchini, Eva Negri, et al. 2005. "Monitoring the Decrease in Breast Cancer Mortality in Europe." European Journal of Cancer Prevention Vol. 14: 497-502.

Li, H., M. Stampfer, J. Hollis, L. Mucci, J. Gaziano, D. Hunter, E. Giovannucci, and J. Ma. 2007. "A Prospective Study of Plasma Vitamin D Metabolites, Vitamin D Receptor Polymorphisms, and Prostate Cancer." Public Library of Science Vol. 4(3): 562-571.
Lumey, L.H., B. Pittman, E.A. Zang, and E.L. Wynder. 1997. "Cigarette Smoking and Prostate Cancer: No Relation with Six Measures of Lifetime Smoking Habits in a Large CaseControl Study Among U.S. Whites." Prostate Vol. 33(3): 195-200.
Lu-Yao, G., P. Albersen, D. Moore, W. Shih, Y. Lin, R. DiPaola, and S. Yao. 2008. "Survival Following Primary Androgen Deprivation Therapy among Men with Localized Prostate Cancer." Journal of the American Medical Association Vol. 300(2): 173-81.
Macinko, James, Barbara Starfield, and Leiyu Shi. 2003. "The Contribution of Primary Care Systems to Health Outcomes within Organization for Economic Cooperation and Development (OECD) Countries, 1970-1998." Health Services Research Vol. 38(3): 831-865.
Mariotto, A, E.J. Feuer, L.C. Harlan, L.M. Wun, et al. 2002. "Trends in Use of Adjuvant Multiagent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 19751999." Journal of the National Cancer Institute Vol. 94: 1626-34.

McKinsey Global Institute. 2008. Accounting for the Cost of US Health Care: A New Look at Why Americans Spend More. McKinsey \& Company. NP.
Michaud, P.C., D. Goldman, D. Lakdawalla, A. Gailey, and Y. Zheng. 2009. "International Differences in Longevity and Health and their Economic Consequences." Manuscript, RAND Corporation. Santa Monica, California.
Moise, Pierre. 2003. "The Heart of the Health Care System: Summary of the Ischaemic Heart Disease Part of the OECD Ageing-Related Diseases Study" pp. 27-52 in Organisation for Economic Co-operation and Development. 2003. A Disease-Based Comparison of Health Systems: What is Best and at What Cost? OECD. Paris.
Møller, B., H. Weedon-Fekjær, T. Hakulinen, L. Tryggvadóttir, et al. 2005. "The Influence of Mammographic Screening on National Trends in Breast Cancer Incidence." European Journal of Cancer Prevention Vol. 14(2): 1117-128.
Nolte, Ellen and C. Martin McKee. 2008. "Measuring the Health of Nations: Updating an Earlier Analysis." Health Affairs Vol. 27(1): 58-71.
Ogawa, Kazuhiko, Katsumasa Nakamura, Tomonari Sasaki, Hiroshi Onishi, et al. 2008. "Radical External Beam Radiotherapy for Prostate Cancer in Japan: Differences in the Patterns of Care among Japan, Germany, and the United States." Radiation Medicine Vol. 26: 57-52.
Organisation for Economic Co-operation and Development. 2003. Stroke Care in OECD Countries: A comparison of Treatment, Costs and Outcomes in 17 Countries. Health Working Paper \#5.
Organisation for Economic Co-operation and Development. 2006. Health Care Quality Indicators Project: Initial Indicators Report. OECD Health Working paper \#22.
Organisation for Economic Co-operation and Development. 2007. Health Care Quality Indicators Project 2006: Data Collection Update Report. Working paper \#29.
Organisation for Economic Co-operation and Development (OECD). 2008. OECD Health Data 2008: How Does the United States Compare? Organisation for Economic Co-operation and Development. Paris.
Osborne, C. Kent. 1998. "Tamoxifen in the Treatment of Breast cancer." New England Journal of Medicine Vol. 339(22): 1609-1618.
Pilepich, Miljenko V., Kathryn Winter, Colleen A. Lawton, Robert E. Krisch, et al. 2005.
"Androgen Suppression Adjuvant to Definitive Radiotherapy in Prostate Carcinoma -Long-term Results of Phase III RTOG 85-31." International Journal of Radiation Oncology*Biology*Physics Vol. 61(5): 1285-1290.
Pollack, Alan, G. Zagars, G. Starkschall, J. Antolak, J. Lee, E. Huang, A. von Eschenback, D. Kuban, and I. Rosen. 2002. "Prostate Cancer Radiation Dose Response: Results of the M.D. Anderson Phase III Randomized Trial." International Journal of Oncology, Biology, Physics Vol. 53(5): 1097-1105.
Post, P.N., R.A.M. Damhuis, A.P.M. van der Meyden, and the EUROCARE Working Group. 1998. "Variation in Survival of Patients with Prostate Cancer in Europe Since 1978." European Journal of Cancer Vol. 34(14): 2226-2231.

Potosky, Arnold L., Eric J. Feuer, and David L. Levin. 2001. "Impact of Screening on Incidence and Mortality of Prostate Cancer in the United States." Epidemiologic Reviews Vol. 23(1): 181-186.
Preston, Samuel and Haidong Wang. 2006. "Changing Sex Differentials in Mortality in the United States: The Role of Cohort Smoking Patterns." Demography Vol. 43(4): 413-34.
Preston, Samuel, Dana Glei and John Wilmoth. 2009. "Contribution of Smoking to International Differences in Life Expectancy." Forthcoming in Eileen Crimmins and Samuel Preston, Divergent Trends in Life Expectancy. National Research Council. Washington, D.C.
Quinn, M.J. 2003. "Cancer Trends in the United States—A View From Europe." Journal of the National Cancer Institute Vol. 95(17): 1258-1261.
Ragaz, Joseph, Stewart M. Jackson, Nhu Le, Ian H. Plenderleith, et al. 1997. "Adjuvant Radiotherapy and Chemotherapy in Node-Positive Premenopausal Women with Breast Cancer." New England Journal of Medicine Vol. 337(14): 956-62.
Sandblom, Gabriel, Monika Dufmats, Kerstin Nordenskjöld, and Eberhard Varenhorst. 2000. "Prostate Carcinoma Trends in Three Counties in Sweden 1987-1996: Results from a Population-based National Cancer Register, South-East Region Prostate Cancer Group." Cancer Vol. 88(6): 1445-53.
Sant, Milena, Claudia Allemani, Franco Berrino, Michel P. Coleman, et al. 2004. "Breast Carcinoma Survival in Europe and the United States: A Population-Based Study." Cancer Vol. 100(4):715-22.
Schootman, Mario, Donna Jeffe, Anat Reschke, and Rebecca Aft. 2004. "The Full Potential of Breast Cancer Screening Use to Reduce Mortality Has Not Yet Been Realized in the United States." Breast Cancer Research and Treatment Vol. 85(3): 219-222.
Schröder, Fritz H., Jonas Hugosson, Monique J. Roobol, Teuvo L.J. Tammela, et al. 2009. "Screening and Prostate-Cancer Mortality in a Randomized European Study." New England Journal of Medicine Vol. 360: 1320-8.
Shampo, Mark. 2002. "Development of the PSA Test." Journal of Pelvic Surgery Vol. 8(2): 123126.

Shapiro, Sam, Elizabeth Ann Coleman, Mireille Breeders, Mary Codd, et al. 1998. "Breast Cancer Screening Programmes in 22 Countries: Current Policies, Administration and Guidelines." International Journal of Epidemiology Vol. 27: 735-742
Stattin, Pär, Robert Johansson, Ronald Lodnert, Andrén Ove, et al. 2005. "Geographical Variation in Incidence of Prostate Cancer in Sweden." Scandinavian Journal of Urology and Nephrology Vol. 39(5): 372-379.
Surveillance Epidemiology and End Results (SEER). 2008. Website of the United States National Institutes of Health, National Cancer Institute. Accessed June-August, 2008.

Tarone, Robert E., Kenneth C. Chu, and Otis W. Brawley. 2000. "Implications of Stage-Specific Survival Rates in Assessing Recent Declines in Prostate Cancer Mortality Rates." Epidemiology Vol. 11(2): 167-170.
Technological Change in Health Care (TECH) Research Network. 2001. "Technological Change around the World: Evidence from Heart Attack Care." Health Affairs Vol. 20(3): 25-42.
Thompson, Ian M., Catherine M. Tangen, Jorge Paradelo, M. Scott Lucia, et al. 2006. "Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer: A Randomized Clinical Trial." Journal of the American Medical Association Vol. 296(19): 2329-2335.
Thorpe, Kenneth E., David H. Howard and Katya Galactionova. 2007a. "Differences In Disease Prevalence As a Source of the U.S.-European Health Care Spending Gap." Health Affairs Vol. 26(6): 678-686.
Thorpe, Kenneth E., David H. Howard and Katya Galactionova. 2007b. "Technical Appendix." On-line data supplement to Thorpe et al. 2007a.
Torti, D.C. and G. O. Matheson. 2004. "Exercise and Prostate Cancer." Sports Medicine Vol. 34(6): 363-69.
Trock, B., M. Han, S. Freedland, E. Humphreys, T. DeWeese, A. Partin, and P. Walsh. 2008. "Prostate Cancer-Specific Survival Following Salvage Radiotherapy vs. Observation in Men with Biochemical Recurrence after Radical Prostatectomy." Journal of the American Medical Association Vol. 299(23): 2760-69.
Ugnat, A-M, L. Xie, R. Semenciw, C. Waters, et al. 2005. "Survival Patterns for the Top Four Cancers in Canada: the Effects of Age, Region and Period." European Journal of Cancer Prevention Vol. 14: 91-100.
United States National Center for Health Statistics. 2008. Deaths: Final Data for 2005. National Vital Statistics Reports. Vol. 56(10). Nat. Center for Health Statistics. Hyattsville, MD.
United States National Center for Health Statistics. 2002. Deaths: Final Data for 2000. National Vital Statistics Reports. Vol. 50(15). Nat. Center for Health Statistics. Hyattsville, Md.
U.S. Preventive Services Task Force. 2008. "Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement." Annals of Internal Medicine Vol. 149(3): 185-91.
Vainio, H. and F. Bianchini. 2002. Breast Cancer Screening. IARC Handbooks of Cancer Prevention, Vol. 7. Lyon, France: International Agency for Research on Cancer Press and World Health Organization.
Vercelli, M., A. Quaglia, E. Marani, and S. Parodi. 2000. "Prostate Cancer Incidence and Mortality Trends Among Elderly and Adult Europeans." Critical Reviews in Oncology/Hematology Vol. 35: 133-144.
Verdecchia, Arduino, Silvia Francisci, Hermann Brenner, Gemma Gatta, et al. 2007. "Recent Cancer Survival in Europe: a 2000-02 Period Analysis of EUROCARE-4 Data." Lancet Oncology Vol. 8: 784-96.
Veronesi, Umberto, Natale Cascinelli, Luigi Mariani, Marco Greco, et al. 2002. "Twenty-year Follow-up of a Randomized Study Comparing Breast-conserving Surgery with Radical Mastectomy for Early Breast Cancer." New England J of Medicine Vol. 347(16): 122732.

Veronesi, Umberto, Peter Boyle, Aron Goldhirsch, Roberto Orecchia, et al. 2005. "Breast Cancer." Lancet Vol. 365: 1727-41.
Wells, J. 1998. "Mammography and the Politics of Randomised Controlled Trials." British Medical Journal Vol. 317(31): 1224-30.

Wolf-Maier, K., R. Cooper, H. Kramer, J Banegas, S. Giampaoli, M. Joffres, N. Poulter, P. Primastesta, B. Stegmayr, and M. Thamm. 2004. "Hypertension Treatment and Control in Five European Countries, Canada, and the United States." Hypertension Vol. 43(10):10-17.
Wood, William C. 1994. "Progress from Clinical Trials on Breast Cancer." Cancer Vol. 74(S9): 2606-9.
Wong, Yu-Ning, Nandita Mitra, Gary Hudes, Russell Localio, et al. 2006. "Survival Associated With Treatment vs. Observation of Localized Prostate Cancer in Elderly Men." Journal of the American Medical Association Vol. 296: 2683-2693.
World Health Organization. 2009. World Health Organization Statistical Information System. Website accessed July 2009.
Writing Group for the Women's Health Initiative Investigators. 2002. "Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women's Health Initiative Randomized Controlled Trial." Journal of the American Medical Association Vol. 288: 321-33

Table 1. Five-Year Relative Survival Rates for Cancer of Different Sites, US and European Cancer Registries*

|  | 5-year survival rate (\%) |  |
| :--- | :---: | :---: |
| $\underline{\text { Site }}$ | United States | Europe |
|  |  |  |
| Prostate | 99.3 | 77.5 |
| Skin melanoma | 92.3 | 86.1 |
| Breast | 90.1 | 79.0 |
| Corpus uteri | 82.3 | 78.0 |
| Colorectum | 65.5 | 56.2 |
| Non-Hodgkin lymphoma | 62.0 | 54.6 |
| Stomach | 25.0 | 24.9 |
| Lung | 15.7 | 10.9 |
|  |  |  |
|  |  |  |
| All malignancies (men) | 66.3 | 47.3 |
| All malignancies (women) | 62.9 | 55.8 |

*Based on period survival data for 2000-02
Source: Verdecchia et al. (2007).

Table 2. Indicators of Frequency of PSA Testing Among Males
A. Percent of Men Ever Receiving a PSA Test

| Country | Percentage of Men Ever <br> Receiving a PSA Test | Year | Age Group | Source |
| :--- | :---: | :---: | :---: | :---: |
| Australia | $49 \%$ | 2003 | $40+$ | 1 |
| Austria | $54.6 \%$ | $2006-2007$ | $40+$ | 2 |
| Canada | $47.5 \%^{6}$ | $2000-2001$ | $50+$ | 3 |
| France | $36 \%$ | 2005 | $40-74$ | 4 |
| Italy | $31.4 \%$ | 2003 | $50+$ | 5 |
| Netherlands | $12.7 \%^{6}$ | 1994 | $55-74$ | 6 |
| (Rotterdam) | $10 \%$ | "Early 1990 s" $^{\text {Switzerland }}$ |  | $65+$ |
| (Vaud and Neuchâtel |  |  |  | 7 |
| Cantons) | $75 \%$ (BRFSS) | 2001 | $50+$ | 8 |
| United States | $62.7 \%$ (NHIS) |  |  |  |

B. Percent of Men Recently Receiving a PSA Test

| Country | Percentage of Men <br> Receiving a PSA Test in <br> the Past x Years | x | Year | Age <br> Group | Source |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Australia | $27 \%$ | 2 | $1995 / 1996$ | $50+$ | 10 |
| Austria | $31.1 \%$ | 1 | $2006-2007$ | $40+$ | 2 |
| Belgium <br> (Limburg Province) | $23 \%$ | 1 | $1996-1998$ | $40+$ | 11 |
| Canada | $26 \%$ | 1 | $2000-2001$ | $40+$ | 12 |
| Italy | $15.9 \%$ | 2002 | $50+$ | 5 |  |
| Netherlands <br> (Rotterdam) | $20.2 \%$ | $1997-2000$ | $55-74$ | 13 |  |
| Norway <br> (3 counties) | $7 \%$ | 1 | 1999 | $50-65$ | 14 |
| Spain <br> (Getafe City) | $20.9 \%$ | 2 | $1997-1999$ | $55+$ | 15 |
| Sweden | $25.3 \%^{2}$ | 1 | 2002 | $50+$ | 16 |
| United Kingdom $7 \%$ | 1 | $1999-2001$ | $45-84$ | 17 |  |
| United States | $57 \%$ (BRFSS) | 1 | 2001 | $50+$ | 8 |

[^9]population (aged 50+) for 2000 and 2005 were retrieved from the UN Statistics Division's Common Database and interpolated to give a figure for 2002 of 1,699,442.

## References to Table 2:

(1) Holden, Carol A., Damien J. Jolley, Robert I. McLachlan, Marian Pitts, Robert Cumming, Gary Wittert, David J. Handelsman, and David M. de Kretser. 2006. "Men in Australia Telephone Survey (MATeS): Predictors of Men's Help-seeking Behaviour for Reproductive Health Disorders." Medical Journal of Australia Vol. 185(8): 418-22.
(2) Klimont, Jeannette, Josef Ktir, and Barbara Leitner. 2007. Österreichische gesundheitsbefragung 2006/2007: hauptergebnisse und methodische Dokumentation. Statistik Austria. Federal Ministry of Health, Family and Youth. http://www.bmgfj.gv.at (accessed July 15, 2008).
(3) Beaulac, Jennifer A., Richard N. Fry, and Jay Onysko. 2006. "Lifetime and Recent Prostate Specific Antigen (PSA) Screening of Men for Prostate Cancer in Canada." Canadian Journal of Public Health Vol. 97(3): 171-6.
(4) Eisinger, François, Jean-Yves Blay, Jean- François Morère, Olivier Rixe, Anne CalazelBenque, Laurent Cals, Yvan Coscas, Sylvie Dolbeault, Moïse Namer, Daniel Serin, Claire Roussel, and Xavier Pivot. 2008. "Cancer Screening in France: Subjects’ and Physicians' Attitudes." Cancer Causes and Control Vol. 19(4): 431-434.
(5) D'Ambrosio, G., F. Samani, M. Cancian, and C. De Mola. 2004. "Practice of Opportunistic Prostate-Specific Antigen Screening in Italy: Data from the Health Search Database." European Journal of Cancer Prevention Vol. 13(5): 383-6.
(6) Beemsterboer P.M.M., H.J. de Koning, R. Kranse, T.H. Trienekens, P.J. van der Maas, and F.H. Schröder. 2000. "Prostate Specific Antigen Testing and Digital Rectal Examination Before and During a Randomized Trial of Screening for Prostate Cancer: European Randomized Study of Screening for Prostate Cancer, Rotterdam." Journal of Urology Vol. 164: 1216-1220.
(7) Levi, F., C, La Vecchia, L. Randimbison, G. Erler, V.-C. Te, and S. Franceschi. 1998. "Incidence, Mortality, and Survival from Prostate Cancer in Vaud and Neuchatel, Switzerland, 1974-1994." Annals of Oncology Vol. 9(1): 31-5.
(8) Sirovich, Brenda E., Lisa M. Schwartz, and Steven Woloshin. 2003. "Screening Men for Prostate and Colorectal Cancer in the United States: Does Practice Reflect the Evidence?" Journal of the American Medical Association Vol. 289: 1414-1420.
(9) Ross, Louie E., Zahava Berkowitz, and Donatus U. Ekwueme. 2008. "Use of the ProstateSpecific Antigen Test Among U.S. Men: Findings from the 2005 National Health Interview Survey." Cancer Epidemiology Biomarkers \& Prevention Vol. 17(3): 636-44.
(10) Smith, David P. and Bruce K. Armstrong. 1998. "Prostate-Specific Antigen Testing in Australia and Association with Prostate Cancer Incidence in New South Wales." Medical Journal of Australia Vol. 169: 17-20.
(11) Lousbergh, D., F. Buntinx, G. Geys, M. Du Bois, D. Dhollander, and G. Molenberghs. 2002. "Prostate-Specific Antigen Screening Coverage and Prostate Cancer Incidence Rates in the Belgian Province of Limburg in 1996-1998." European Journal of Cancer Prevention Vol. 11(6): 547-549.
(12) Gibbons, Laurie, and Chris Waters. 2003. "Prostate Cancer - Testing, Incidence, Surgery and Mortality." Health Reports Vol. 14(3): 19-20.
(13) Otto, Suzie J., Ingrid W. Van der Crusijen, Michael K. Liem, Ida J. Korfage, Jan J. Lous, Fritz H. Schröder, and Harry J. De Koning. 2003. "Effective PSA Contamination in the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer." International Journal of Cancer Vol. 105(3): 394-399.
(14) Zappa, M., C. Visioli, E. Crocetti, C. Buonamici, A. Baccini, S. Taddei, and S. Ciatto. 2003. "Practice of Opportunistic PSA Screening in the Florence District." Cancer Prevention Vol. 12: 201-204.
(15) Páez, Alvaro, Marcos Luján, Luis Llanes, Ignacio Romero, M. Angel de la Cal, Elena Miravalles, and Antonio Berenguer. 2002. "PSA-Use in a Spanish Industrial Area." European Urology Vol. 41: 162-166.
(16) Sennfalt, Karin, Per Carlsson, and Eberhard Varenhorst. 2006. "Diffusion and Economic Consequences of Health Technologies in Prostate Cancer Care in Sweden, 1991-2002." European Urology Vol. 49: 1028-1034.
(17) Melia, Jane, Penny Coulson, Louise Johns, and Sue Moss. 2003. Report to the Department of Health: Study to Assess the Rate of PSA Testing in Men with No Previous Diagnosis of Prostate Cancer. Cancer Screening Evaluation Unit. Surrey, England. http://www.cancerscreening.nhs.uk/prostate/psa-tests.html (accessed July 22, 2008).

Table 3. Percentage of Women Receiving a Mammogram in Previous Two Years: 1994 and $2003^{1}$

| Country | Earlier Year |  |  |  | Later Year |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | \% <br> Screened | Year | Age Group | Source | \% <br> Screened | Year | Age Group | Source |
| Australia | 51.4 | 1996-7 | 50-69 | 1 | 55.6 | $\begin{gathered} 2003- \\ 2004 \end{gathered}$ | 50-69 | 10 |
| Austria | $\begin{aligned} & 23.1 \\ & 35.7 \end{aligned}$ | 1995 | $\begin{gathered} 40-79 \\ 50-54 \end{gathered}$ | 2 |  |  |  |  |
| Belgium | 49.2 | 1997 | 50-69 | 3 | 54.0 | 2003 | 50-69 | 10 |
| Canada | 50 | 1994 | 50+ | 4 | 70.6 | 2003 | 50-69 | 10 |
| Finland |  |  |  |  | 87.7 | 2003 | 50-59 | 10 |
| France |  |  |  |  | 72.8 | 2003 | 50-69 | 10 |
| Hungary |  |  |  |  | 60.2 | 2003 | 45-65 | 10 |
| Iceland |  |  |  |  | 62.0 | 2003 | 40-69 | 10 |
| Ireland |  |  |  |  | 79.5 | 2003 | 50-64 | 10 |
| Italy |  |  |  |  | 29.0 | 2000 | 55-69 | 11 |
| Japan |  |  |  |  | 2.6 | 2003 | 50-69 | 10 |
| Luxembourg |  |  |  |  | 62.4 | 2003 | 50-69 | 10 |
| Netherlands | 53.2 | 1994 | 50-69 | 5 | 79.0 | 2003 | 50-75 | 11 |
| New Zealand |  |  |  |  | 62.3 | 2003 | 50-64 | 10 |
| Norway |  |  |  |  | 98.0 | 2003 | 50-69 | 10 |
| Portugal |  |  |  |  | 60.1 | 2003 | 50-69 | 10 |
| Spain | 28 | 1994 | 40-70 | 6 |  |  |  |  |
| Sweden |  |  |  |  | 83.6 | 2004 | 50-74 | 10 |
| Switzerland ${ }^{2}$ | 20 | 1992-3 | 50-64 | 7 | 27.0 | 2002 | 50-69 | 11 |
| United Kingdom ${ }^{3}$ | 63.9 | 1995 | 50-64 | 8 | 74.7 | 2003 | 50-64 | 10 |
| United States | 66.5 | 1994 | 50-64 | 9 | 76.0 | 2003 | 50-69 | 10 |

${ }^{1}$ For later years, when there are two observations for the same country we use survey rather than program data in order to maximize comparability with the US (this affected only Canada and the Netherlands).
${ }^{2}$ For 1992-93, the data for Switzerland is for the canton of Vaud only, and the screening interval is 1 year.
${ }^{3}$ For the UK, the recall period is 3 years.

## References to Table 3:

(1) Australian Institute of Health and Welfare. 2008. BreastScreen Australia monitoring report 2004-2005. Cancer series no. 42. Cat. no. CAN 37. Australian Institute of Health and Welfare. Canberra.
(2) Vutuc Ch, G. Haidinger, T. Waldhoer. 1998. "Prevalence of self-reported screening mammography and impact on breast cancer mortality in Austria." Wien Klin Wschr 110:

485-490.
(3) Capet, Francis, Marc Arbyn, and Marisa Abarca. 2003. Mammografische opsporing van borstkanker in België: analyse van de gezondheidsenquêtes 1997 en 2001. IPH / EPI REPORTS Nr. 2003- 008. Brussels.
(4) Snider, Judy, Janet Beauvais, Isra Levy, Paul Villeneueve, and Jennifer Pennock. 1997. "Trends in Mammography and Pap Smear Utilization in Canada." Chronic Diseases in Canada 17(3): 1-15.
(5) Centraal Bureau voor de Statistiek. 2009. Website accessed June-August 2009 (http://statline.cbs.nl/StatWeb/default.aspx).
(6) Luengo, S., P. Lazrao, R. Madero, F. Alvirac, et al. 1996. "Equity in the access to mammography in Spain." Social Science \& Medicine 43(8): 1263-1271.
(7) Bulliard, J.-L., J.-P. De Landtsheer, and F. Levi. 2003. "Results from the Swiss mammography screening pilot programme." European Journal of Cancer 39: 1761-1769.
(8) Department of Health. 1999. "Breast Screening Programme, England 1997-98." Website accessed June-August 2009
(http://www.dh.gov.uk/en/Publicationsandstatistics/Statistics/StatisticalWorkAreas/Statistical healthcare/DH_4016216).
(9) National Center for Health Statistics. 2000. Health, United States, 2000. National Center for Health Statistics. Hyattsville, MD.
(10) OECD Health Data 2008. 2008. Website accessed June-August 2009.
(11) Organisation for Economic Co-operation and Development. 2006. Health Care Quality Indicators Project: Initial Indicators Report. OECD Health Working paper \#2.

Table 4. Coefficients of Negative Binomial Regression Predicting the Log of the Number of Deaths from Prostate and Breast Cancer

| Variable | Coefficient (standard error) |  |
| :---: | :---: | :---: |
|  | Prostate Cancer | Breast Cancer |
| Constant | $\begin{gathered} -10.37^{* * *} \\ (0.079) \end{gathered}$ | $\begin{gathered} -7.657^{* * *} \\ (0.067) \end{gathered}$ |
| Age |  |  |
| 50-54 | $\begin{gathered} 0.000 \\ (-) \end{gathered}$ | $\begin{gathered} 0.000 \\ (-) \end{gathered}$ |
| 55-59 | $\begin{aligned} & 1.166^{* * *} \\ & (0.026) \end{aligned}$ | $\begin{aligned} & 0.247^{* * *} \\ & (0.013) \end{aligned}$ |
| 60-64 | $\begin{aligned} & 2.159^{* * *} \\ & (0.026) \end{aligned}$ | $\begin{aligned} & 0.413^{* * *} \\ & (0.019) \end{aligned}$ |
| 65-69 | $\begin{aligned} & 3.013^{* * *} \\ & (0.032) \end{aligned}$ | $\begin{aligned} & 0.550 * * \\ & (0.024) \end{aligned}$ |
| 70-74 | $\begin{aligned} & 3.744^{* * *} \\ & (0.034) \end{aligned}$ | $\begin{gathered} 0.721 * * \\ (0.029) \end{gathered}$ |
| 75-79 | $\begin{aligned} & 4.384^{* * *} \\ & (0.038) \end{aligned}$ | $\begin{aligned} & 0.925^{* * *} \\ & (0.032) \end{aligned}$ |
| 80-84 | $\begin{gathered} 4.942^{* * *} \\ (0.041) \end{gathered}$ | $\begin{aligned} & 1.157^{* * *} \\ & (0.038) \end{aligned}$ |
| 85+ | $\begin{aligned} & 5.455^{* * *} \\ & (0.047) \end{aligned}$ | $\begin{aligned} & 1.520^{* * *} \\ & (0.046) \end{aligned}$ |
| Period |  |  |
| 1982-1985 | $\begin{gathered} 0.000 \\ (-) \end{gathered}$ | $\begin{gathered} 0.000 \\ (-) \end{gathered}$ |
| 1986-1989 | $\begin{gathered} 0.0586^{* *} \\ (0.010) \end{gathered}$ | $\begin{gathered} 0.0350 * * \\ (0.011) \end{gathered}$ |
| 1990-1993 | $\begin{aligned} & 0.103^{* * *} \\ & (0.016) \end{aligned}$ | $\begin{aligned} & 0.0276 \\ & (0.015) \end{aligned}$ |
| 1994-1997 | $\begin{gathered} 0.0837^{* * *} \\ (0.023) \end{gathered}$ | $\begin{gathered} -0.00241 \\ (0.028) \end{gathered}$ |
| 1998-2001 | $\begin{aligned} & 0.0242 \\ & (0.029) \end{aligned}$ | $\begin{gathered} -0.0741^{*} \\ (0.037) \end{gathered}$ |
| 2002-2005 | $\begin{gathered} -0.0529 \\ (0.036) \end{gathered}$ | $\begin{gathered} -0.114^{* *} \\ (0.042) \end{gathered}$ |
| Observation from US | $\begin{gathered} 0.125 \\ (0.080) \end{gathered}$ | $\begin{gathered} 0.108 \\ (0.082) \end{gathered}$ |

Observation from US in

| 1982-1985 | 0.000 | 0.000 |
| :---: | :---: | :---: |
|  | (-) | (-) |
| 1986-1989 | -0.0229* | -0.0216* |
|  | (0.010) | (0.011) |
| 1990-1993 | -0.00278 | -0.0225 |
|  | (0.015) | (0.015) |
| 1994-1997 | -0.0850*** | -0.0585 ${ }^{*}$ |
|  | (0.023) | (0.028) |
| 1998-2001 | -0.215*** | -0.0892* |
|  | (0.029) | (0.036) |
| 2002-2005 | -0.274*** | -0.126** |
|  | (0.036) | (0.040) |

Figure 1. Age Standardized Death Rates at Ages 50+ From Influenza, 2000-2004


Figure 2. Age Standardized Death Rates at Ages 50+ From Pneumonia, 2000-2004


Figure 3. Age-Standardized Death Rates From Prostate Cancer, 1980-2005


Figure 4. Age-Standardized Death Rates From Breast Cancer, 1980-2005



[^0]:    * This research was supported by the U.S. Social Security Administration through grant \#10-M-98363-1-01 to the National Bureau of Economic Research as part of the SSA Retirement Research Consortium. The findings and conclusions expressed are solely those of the authors and do not represent the views of SSA, any agency of the Federal Government, or the NBER. We are grateful to Beth Soldo, Jason Schnittker, and Eileen Crimmins for comments and suggestions.

[^1]:    ${ }^{1}$ Ages vary somewhat but the variation is thought to be a "minor threat" to the validity of comparisons (OECD 2006:69). The 15 countries include 6 for whom the recall period is greater than 3 years, the period used in the US.

[^2]:    ${ }^{2}$ The US figure for cholesterol is drawn from the Medicare Expenditure Panel Survey because HRS did not gather this information.

[^3]:    ${ }^{3}$ Data on treatments at ages 85-89 were not available for Spain or the United Kingdom.

[^4]:    ${ }^{4}$ The strategy adopted by Nolte and McKee is no different from saying that genetic factors play some role in cardiovascular mortality and, as a consequence, attributing half of international variation in cardiovascular mortality to genetic factors.

[^5]:    ${ }^{5}$ It has been claimed that this number includes 10 million people who are in fact covered by Medicaid insurance but who fail to report it (Ohsfeldt and Schneider 2006).

[^6]:    ${ }^{6}$ Of the two sources of US data presented in Table 2, the BRFSS data are less reliable because they are based on a telephone survey with a low response rate.

[^7]:    ${ }^{7}$ The data are for males and refer to the age-adjusted rates for all ages.

[^8]:    ${ }^{8}$ These rates are taken from the International Agency for Research on Cancer (http://www-dep.iarc.fr/), which extracts the World Health Organization mortality data and standardizes the rates to the world population in 1960 (Segi world standard).

[^9]:    ${ }^{1}$ This figure does not include men with a history of prostate cancer.
    ${ }^{2}$ According to Sennfalt, Carlsson, and Varenhorst (2006), 430,000 PSA tests were performed in Sweden in 2002.
    We assume that all were performed on men aged 50+. The UN Population Division's estimates for Sweden's male

